Introduces Highly Purified Human Apo-eIF4E Protein and Its Complexes With EIF4G and 4E-BP1 for Research and Screening eIF4E Inhibitors
Aurora Biolabs, Inc. (ABL) is excited to announce that we are starting to offer highly purified eIF4E proteins for research and drug discovery.
Control of mRNA translation plays a critical role in cell growth, proliferation, differentiation, and anti-cancer drug discovery. A key player in the regulation of this process is the mRNA 5′ cap-binding protein, eukaryotic translation initiation factor 4E (eIF4E). Human EIF4E is a eukaryotic translation initiation factor involved in directing ribosomes to the cap structure of mRNAs. EIF4E is part of the EIF4F pre-initiation complex, which is made up of EIF4E, and EIF4G. Almost all cellular proteins require EIF4E in order to be translated into protein. EIF4E binds the first nucleotide on the 5' end of an mRNA molecule (known as the cap): a 7-Methylguanosine (m7G). It sandwiches m7G between 2 tryptophan residues, and other amino acids that are involved in the binding.
Many studies report that eIF4E is overexpressed in almost 100% of tumors within the breast, head, neck, and colon. Several retrospective studies indicate that eIF4E overexpression is correlated with poor prognosis. Reported data indicate that the inhibition of eIF4E in tumor cell lines and xenograft models impairs tumor growth and induces apoptosis; eIF4E, therefore, can be considered a valuable target for cancer therapy. Targeting the cap-binding pocket of eIF4E should represent a way to inhibit all the eIF4E cellular functions.
Human Recombinant EIF4E is expressed in E. Coli as a single, non-glycosylated polypeptide chain containing 237 amino acids, EIF4E (1-217 a.a.) with a N-terminal His-Tag. A fragment of 80 residues of EIF4G containing EIF4E binding domain is co-expressed with EIF4E. The binary complex is purified by affinity, ion exchange, and gel filtration chromatographic techniques. We also offer 4E-BP1 peptide or its complex with eIF4E for binding study.
The eIF4E proteins described above provide a method to select and develop compounds that specifically inhibit eIF4E/4G and eIF4E/4E-BP1. To learn more about Aurora Biolabs’ eIF4E products, please visit our website at https://aurorabiolabs.com/recombinant-human-eukaryotic-translation-initiation-factor-4e-eif4e-his-tag-538.html.
